drugset / Trial / NCT06608927
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3
Active not recruiting
610 enrolled
Arcus Biosciences, Inc.
Taiho Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Timeline
- Start
- 2024-12-13
- Primary completion
- 2030-11-30
- Completion
- 2030-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quemliclustat | Small molecule | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |